<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский онкологический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-9984</issn><issn publication-format="electronic">2412-9119</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">42991</article-id><article-id pub-id-type="doi">10.18821/1028-9984-2018-23-3-6-180-188</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">INFLUENCE OF CHRONIC NEUROGENIC PAIN ON DYNAMICS OF ENDOTHELIN-1 LEVEL AND COMPONENTS OF NO-SYSTEM DURING MELANOMA B16/F10 GROWTH</article-title><trans-title-group xml:lang="ru"><trans-title>ВЛИЯНИЕ ХРОНИЧЕСКОЙ НЕЙРОГЕННОЙ БОЛИ НА ДИНАМИКУ УРОВНЯ ЭНДОТЕЛИНА-1 И КОМПОНЕНТОВ NO-СИСТЕМЫ В ПРОЦЕССЕ РОСТА МЕЛАНОМЫ B16/F10</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kit</surname><given-names>O. I</given-names></name><name xml:lang="ru"><surname>Кит</surname><given-names>О. И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kotieva</surname><given-names>I. M</given-names></name><name xml:lang="ru"><surname>Котиева</surname><given-names>И. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Frantsiyants</surname><given-names>E. M</given-names></name><name xml:lang="ru"><surname>Франциянц</surname><given-names>Е. М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Surikova</surname><given-names>Ekaterina I.</given-names></name><name xml:lang="ru"><surname>Сурикова</surname><given-names>Екатерина Игоревна</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, PhD, Senior Researcher at Laboratory of Malignant tumor pathogenesis study, Rostov Research Institute of Oncology, 344037, Rostov-on-Don, Russian Federation</p></bio><bio xml:lang="ru"><p>кандидат биологических наук, старший научный сотрудник лаборатории изучения патогенеза злокачественных опухолей ФГБУ «РНИОИ» МЗ РФ, 14-я линия,63, Ростов-на-Дону</p></bio><email>super.gormon@ya.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kaplieva</surname><given-names>I. V</given-names></name><name xml:lang="ru"><surname>Каплиева</surname><given-names>И. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Bandovkina</surname><given-names>V. A</given-names></name><name xml:lang="ru"><surname>Бандовкина</surname><given-names>В. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Trepitaki</surname><given-names>L. K</given-names></name><name xml:lang="ru"><surname>Трепитаки</surname><given-names>Л. К</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pogorelova</surname><given-names>Ju. A</given-names></name><name xml:lang="ru"><surname>Погорелова</surname><given-names>Ю. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Rostov Research Institute of Oncology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Ростовский научно-исследовательский онкологический институт» Министерства здравоохранения РФ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2018</year></pub-date><volume>23</volume><issue>3-6</issue><issue-title xml:lang="en">VOL 23, NO3-6 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 23, №3-6 (2018)</issue-title><fpage>180</fpage><lpage>188</lpage><history><date date-type="received" iso-8601-date="2020-08-24"><day>24</day><month>08</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Эко-Вектор"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjonco.com/1028-9984/article/view/42991">https://rjonco.com/1028-9984/article/view/42991</self-uri><abstract xml:lang="en"><p>Chronic neurogenic pain is a pathogenic factor triggering mechanisms of homeostasis disfunction. As chronic neurogenic pain has been found to affect the biological features of B16/F10 melanoma, the purpose of the study was to determine the levels of endothelin-1 and components of the NO-system in mice during the growth of transplantable B16/F10 melanoma with chronic pain. Methods. The study included 64 female mice. B16/F10 melanoma was transplanted under the skin of the back to animals of the main group 2 weeks after the sciatic nerve ligation. Levels of endothelin-1, NOS-2, NOS-3, L-arginine, citrulline, total nitrite, nitrotyrosine and ADMA were determined by ELISA in the intact skin and in tumor tissues. Results. The dynamics of the studied parameters in tumor growth with and without chronic pain was different. Increased levels of endothelin-1 in the skin and in tumor tissues, stably elevated levels of NO-synthases in the tumor and stably elevated ADMA levels with their decrease by week 3 of the growth were observed in the tumor growth with pain. Conclusions. Chronic pain can contribute to the development of the immune tolerance to tumor antigens in the skin. Conditions are formed that both facilitate the survival of tumor cells and contribute to the further development of melanoma. The dynamics of activity of endothelin-1 and NO systems can promote stimulation of the epithelial-mesenchymal transition, enhance tumor invasion and hemangio- and lymphangiogenesis. Changes in the ADMA inhibitor levels in the tumor growth with chronic pain may indicate a more subtle control of the NO level providing increased melanoma invasiveness.</p></abstract><trans-abstract xml:lang="ru"><p>Хроническая нейрогенная боль является патогенным фактором, запускающим механизмы нарушения гомеостаза. В связи с обнаружением влияния хронической нейрогенной боли на биологические особенности меланомы B16/F10 целью работы было изучение уровня эндотелина-1 и компонентов NO-системы у мышей в процессе роста перевивной меланомы B16/F10 на фоне хронической боли. Методы. Работа выполнена на 64 мышах-самках. Животным основной группы меланому В16/F10 перевивали под кожу спины через 2 нед после перевязки седалищных нервов. Содержание эндотелина-1, NOS-2, NOS-3, L-аргинина, цитруллина, общего нитрита, нитротирозина и АДМА определяли методом ИФА в непоражённой опухолью коже и в ткани опухоли. Результаты. Обнаружены различия в динамике изученных показателей при обычном росте меланомы и росте опухоли на фоне хронической боли. При росте опухоли на фоне боли выявлено увеличение уровня эндотелина-1 как в коже, так и в опухоли в процессе роста, стабильно повышенный уровень NO-синтаз в опухоли, стабильно повышенный уровень АДМА и его снижение к 3-й нед роста. Заключение. Состояние хронической боли может способствовать развитию в коже состояния иммунологической толерантности к опухолевым антигенам. Формируются условия, не только облегчающие выживание опухолевых клеток, но и благоприятствующие дальнейшему развитию меланомы. Динамика активности систем эндотелина-1 и NO может способствовать стимуляции процессов эпителиально-мезенхимального перехода, усиления инвазивности опухоли, гемангио- и лимфангиогенеза. Изменение уровня ингибитора АДМА в условиях роста опухоли на фоне хронической боли может свидетельствовать о более тонком контроле уровня NO, обеспечивающего повышенную инвазивность меланомы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>B16/F10 melanoma</kwd><kwd>chronic neurogenic pain</kwd><kwd>skin</kwd><kwd>tumor</kwd><kwd>mice</kwd><kwd>endothelin-1</kwd><kwd>NO-system</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>меланома B16/F10</kwd><kwd>хроническая боль</kwd><kwd>кожа</kwd><kwd>опухоль</kwd><kwd>мыши</kwd><kwd>эндотелин-1</kwd><kwd>NO-система</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Данилов А.Б., Давыдов О.С. Эпидемиология нейропатической боли. Ж. Боль. 2007; 17 (4): 12-16.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Яхно Н.Н., Кукушкин М.Л., Давыдов О.С., Данилов А.Б., Амелин А.В., Куликов С.М. Результаты Российского эпидемиологического исследования распространенности нейропатической боли, ее причин и характеристик в популяции амбулаторных больных, обратившихся к врачу-неврологу. Ж. Боль. 2008; 18 (3): 24-32.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Worldwide palliative care alliance (WPCA); World Health Organization. 2015. www.who.int/nmh/Global_Atlas_of_Palliative_ Care.pdf</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Paice J.A., Bell R.F., Kalso E.A., Soyannwo O.A. Cancer Pain. From Molecules to Saffering. IASP Press. Seattle; 2010.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Кукушкин М.Л. Этиопатегенетические принципы лечения хронической боли. Русский мед. журнал. 2007; 15 (10): 827-32.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Кит О.И., Франциянц Е.М., Котиева И.М., Каплиева И.В., Трепитаки Л.К., Бандовкина В.А. и др. Некоторые механизмы повышения злокачественности меланомы на фоне хронической боли у самок мышей. Российский журнал боли. 2017; 53 (2): 14-20.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Saleh A., Stathopoulou M.G., Dadé S., Ndiaye N.C., Azimi-Nezhad M., Murray H. et al. Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Med Genet. 2015. doi: 10.1186/s12881-015-0234-6.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lankhorst S., Danser A.H., van den Meiracker A.H. Endothelin-1 and antiangiogenesis. Am. J. Physiol Regul. Integr. Comp. Physiol. 2016, 310 (3):230-4. doi: 10.1152/ajpregu.00373.2015.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Smith T.P., Haymond T., Smith S.N., Sweitzer S.M. Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain. Journal of pain research. 2014; (7): 531-4.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Yang Y., Zhang J., Liu Y., Zheng Y., Bo J., Zhou X. et al. Role of nitric oxide synthase in the development of bone cancer pain and effect of L-NMMA. Mol. Med. Rep. 2016, 13(2):1220-1226. doi: 10.3892/mmr. 2015.4647.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Koschembahr A.M. von, Swope V.B., Starner R.J., Abdel-Malek Z.A. Endothelin-1 protects human melanocytes from UV-induced DNA damage by activating JNK and p38 signaling pathways. Exp. Dermatol. 2015. doi: 10.1111/exd.12638.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Willey K.E. Davenport A.P. Nitric oxide-medulation of the endothelin-1 signaling pathway in the human cardiovascular system. Brit. J. Pharmacology. 2001; 132: 213-20.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pirtskhalaishvili G., Nelson J.B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000; 44 (1): 77-87.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Lalich M., McNeel D.G., Wilding G., Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007; 25 (8): 785-94.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rosanò L., Spinella F., Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat.Rev. Cancer. 2013а; 13: 637-51.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Davenport A.P. Hyndman K.A., Dhaun N., Southan C. et al. Endothelin. Pharmacological reviews. 2016; 68 (2): 357-418.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bagnato A., Rosan Õ.L, Spinella F., Di Castro V., Tecce R., Natali P.G. Endothelin B receptor blockade inhibits dynamic of cell interactions and communications in melanoma cell progression. Cancer Research. 2004; 64: 1436-43.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Murase D. Cooperation of endothelin-1 signaling with melanosomes plays a role in developing and/or maintaining human skin hyperpigmentation Biol. Open. 2015; 4 (10): 1213-21.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Irani S., Salajegheh A., Smith R.A., Lam A.K. A review of the profile of endothelin axis in cancer and its management. Crit. Rev. Oncol. Hematol. 2014; 89: 314-21.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Papanikolaou S., Bravou V., Papadaki H., Gyftopoulos K. The role of the endothelin axis in promoting epithelial to mesenchymal transition and lymph node metastasis in prostate adenocarcinoma. Urol. Ann. 2017, 9(4):372-379. doi: 10.4103/UA.UA_43_17.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Wu M.H., Huang C.Y., Lin J.A., Wang S.W., Peng C.Y., Cheng H.C., Tang CH. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene. 2014; 33 (13): 1725-35. doi: 10.1038/onc.2013.109.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Shi L., Zhou S.S., Chen W.B., Xu L. Functions of endothelin-1 in apoptosis and migration in hepatocellular carcinoma. Exp. Ther. Med. 2017, 13(6):3116-3122. doi: 10.3892/etm.2017.4314.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Nelson J.B., Udan M.S., Guruli G., Pflug B.R. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia. 2005; 7 (7): 631-7.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Lankhorst S., Kappers M.H., van Esch J.H., Danser A.H., van den Meiracker A.H. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid. Redox Signal. 2014; 20 (1): 135-45. doi: 10.1089/ars.2013.5244.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Vahora H., Khan M.A., Alalami U., Hussain A. The Potential Role of Nitric Oxide in Halting Cancer Progression Through Chemoprevention. J. Cancer Prev. 2016; 21 (1): 1-12. doi: 10.15430/JCP.2016.21.1.1. Epub 2016 Mar 30.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Lahdenranta J., Hagendoorn J., Padera T.P., Hoshida T., Nelson G., Kashiwagi, S. Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res. 2009; 69: 2801-8.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Ridnour L.A., Windhausen A.N., Isenberg J.S., Yeung N., Thomas D.D., Vitek M.P. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc. Natl. Acad. Sci. U S A. 2007; 104: 16898-903.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P. et al. Myeloid suppressor lines inhibit T-cell responses by an NO-dependent mechanism. J. Immunol. 2002; 168: 689-95.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L. et al. Altered recognition of antigen is a mechanism of CD8+ T-cell tolerance in cancer. Nat. Med. 2007; (13): 828-35.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Rodriguez P.C., Quiceno D.G., Ochoa A.C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. 2007; 109: 1568-73.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Viola A., Bronte V. Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin. Cancer Biol. 2007; 17(4): 309-16.</mixed-citation></ref></ref-list></back></article>
